Is MIPS 385 the same as MIPS 385?

Yes. CMS uses zero-padded three-digit Quality IDs (385) in official specifications, while clinicians often search for MIPS 385 or Quality ID 385 without the leading zero. Both refer to the same 2026 MIPS quality measure reported through the Quality Payment Program (QPP).

How do I report MIPS Measure 385 in 2026?

MIPS Measure 385 (Quality ID 385) is reported through the Quality Payment Program (QPP) as a MIPS Clinical Quality Measure (CQM) via qualified registry, or Medicare Part B claims where applicable.

Is MIPS 385 a topped-out measure?

No, MIPS 385 is not topped out, meaning there is still meaningful performance variation across clinicians.

Measure ID: MIPS 385|Ophthalmology|2026 Performance Year

2026 MIPS Measure #385: Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement

Patients aged 18 years and older who had surgery for primary rhegmatogenous retinal detachment and achieved an improvement in their visual acuity, from their preoperative level, within 90 days of surgery in the operative eye.

Outcome – High PriorityOphthalmologyPatient Safety

Measure ID:MIPS 385 (Quality ID 385)

Collection:MIPS CQM

Topped Out:No

View CMS Spec ↗

Measure Specification

Eligible Population

Patients aged ≥ 18 years on the date of the procedure

ANDPatient procedure during the performance period

Exclusions

M1453Patients with a pre-operative visual acuity better than 20/40

G9757Surgical procedures that included the use of silicone oil

Numerator

Patients who achieved an improvement in their visual acuity, from their preoperative level, within 90 days of surgery in the operative eye.

Reporting Codes

Performance Met:

G9516Patient achieved an improvement in visual acuity, from their preoperative level, within 90 days of surgery

Performance Not Met:

G9517Patient did not achieve an improvement in visual acuity, from their preoperative level, within 90 days of surgery, reason not given

VBCA Insights

Why This Measure Matters

Did the patient's vision improve after retinal detachment surgery? This measures whether your surgical outcomes actually restored function—not just reattached the retina, but improved visual acuity within 90 days. Improvement happens when you use modern surgical techniques, achieve solid reattachment, and manage postoperative inflammation well. Visual improvement is the outcome that matters to patients; it justifies the surgery and reduces the psychological burden of vision loss.

VBCA is a CMS-approved Qualified Clinical Data Registry (QCDR) that submits MIPS Measure 385 to the Quality Payment Program (QPP). Practices can report this measure as a MIPS Clinical Quality Measure (CQM) or through qualified registry submission.

🧮MIPS Score Simulator

Estimate only — actual CMS scoring may vary based on reporting method, data completeness, and annual rule updates.

Your Performance Rate:%Benchmarks vary by collection type

💡 Tip: Enter your performance rate to compare MIPS points across all collection types. The same rate can score differently depending on how you submit.

Specialty Measure Sets

Ophthalmology

Related Measures

Ophthalmology

MIPS 117: Diabetes: Eye Exam MIPS 141: Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 20% OR MIPS 191: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery MIPS 303: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract MIPS 304: Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery MIPS 384: Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating MIPS 389: Cataract Surgery: Difference Between Planned and Final Refraction MIPS 499: Appropriate Screening and Plan of Care for Elevated Intraocular Pressure Following MIPS 500: Acute Posterior Vitreous Detachment Appropriate Examination and Follow-up MIPS 501: Acute Posterior Vitreous Detachment and Acute Vitreous Hemorrhage Appropriate

Patient Safety

MIPS 130: Documentation of Current Medications in the Medical Record MIPS 145: Radiology: Exposure Dose Indices Reported for Procedures Using Fluoroscopy MIPS 155: Falls: Plan of Care MIPS 164: Coronary Artery Bypass Graft (CABG): Prolonged Intubation MIPS 168: Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration MIPS 181: Elder Maltreatment Screen and Follow-Up Plan MIPS 259: Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured MIPS 275: Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before MIPS 286: Dementia: Safety Concern Screening and Follow-Up for Patients with Dementia MIPS 351: Total Knee or Hip Replacement: Venous Thromboembolic and Cardiovascular Risk MIPS 354: Anastomotic Leak Intervention MIPS 355: Unplanned Reoperation within the 30-Day Postoperative Period MIPS 357: Surgical Site Infection (SSI)MIPS 374: Closing the Referral Loop: Receipt of Specialist Report MIPS 384: Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating MIPS 392: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation MIPS 393: Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation,MIPS 413: Door to Puncture Time for Endovascular Stroke Treatment MIPS 422: Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse MIPS 432: Proportion of Patients Sustaining a Bladder or Bowel Injury at the time of any Pelvic MIPS 513: Patient Reported Falls and Plan of Care

Official Resources

📄 CMS Measure Specification (PDF)🔗 QPP Quality Payment Program

Clinical Rationale

For management and treatment for PVD and RRD, the following apply (for goals of treatment): • Prevention of visual loss and functional impairment • Maintenance of quality of life All patients with risk factors should be instructed to notify their ophthalmologist as soon as possible if they have a substantial change in symptoms, such as an increase in floaters, loss of visual field, or decrease in visual acuity develop.

Studies demonstrate that the success rate increases with the recognition of risk factors and the practice of retina subspecialization. International studies report primary rhegmatogenous retinal surgery success rates ranging from 64 to 91%.

Clinical Recommendations

This is an outcome measure. As such, no clinical recommendations are included.

Implementation Notes

This measure contains one strata defined by a single submission criteria. This measure produces a single performance rate. For the purposes of MIPS implementation, this procedure measure is submitted each time a procedure is performed. This is an outcome measure and will be calculated solely using MIPS eligible clinician, group, or third-party intermediary submitted data.

• For patients who receive the surgical procedures specified in the denominator coding, it should be submitted whether or not the patient achieved an improvement of their visual acuity within 90 days of surgery. • Include only procedures performed between January 1st and September 30th of the performance period. This will allow the post-operative period to occur before third-party intermediaries must submit data to CMS.

Report this measure through VBCA

Our QCDR handles measure selection, data validation, and submission—so you can focus on clinical performance.

Learn About Our QCDR →Talk to Us